Mark G. Kris, MD

Mark G. Kris, MD, discusses 1 of the major topics of discussion from the 15th Annual New York Lung Cancers Symposium, among other areas of focus at the meeting.

Mark G. Kris, MD, discusses treatment options for <em>MET</em>-mutant non&ndash;small cell lung cancer.

Mark G. Kris, MD, discusses the importance of delaying relapse in patients with&nbsp;<em>EGFR</em>-positive non&ndash;small cell lung cancer. He shares the significance of the findings from the phase III RELAY trial, where the goal was to delay the time to relapse by adding ramucirumab to erlotinib.

Mark G. Kris, MD, discusses what is most important in treating patients with lung cancer today.

Mark G. Kris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the recent FDA approval of durvalumab (Imfinzi) for the treatment of patients with locally advanced, unresectable stage III non&ndash;small cell lung cancer.

Mark G. Kris, MD, William and Joy Ruane Chair in Thoracic Oncology at Memorial Sloan-Kettering Cancer Center, gives an overview of current guidelines for molecular testing in lung cancer.